Conditionnement : 25mg
Téléphone : +1 850 650 7790
Synonyms: B/B Homodimerizer
| Description | AP20187 (B/B Homodimerizer) is a cell-permeable compound used to dimerize FK506-binding protein (FKBP) fusion proteins, thereby initiating biological signaling cascades, gene expression, or disrupting protein-protein interactions. |
| In vitro | Treatment of LNCaP cells with AP20187 (B/B Homodimerizer) at a concentration of 100 nM significantly reduces ro-iCaspase-9 levels, while the smaller, processed, active form of caspase-9 becomes evident. |
| In vivo | Treatment with AP20187 significantly mitigates the effects of experimental autoimmune encephalomyelitis (EAE) on myelin sheaths in mice, markedly decreasing the prevalence of deteriorating axons and enhancing axonal density within demyelination sites in the lumbar spinal cord of PLP/Fv2E-PERK mice. Additionally, real-time PCR analysis reveals that AP20187 (B/B Homodimerizer) administration at doses of 0.5 mg/kg, 2 mg/kg, or 5 mg/kg notably elevates CHOP mRNA levels in the central nervous system (CNS) of PLP/Fv2E-PERK mice at post-infection day (PID) 12. |
| Synonyms | B/B Homodimerizer |
| Molecular Weight | 1482.75 |
| Formula | C82H107N5O20 |
| Cas No. | 195514-80-8 |
| Smiles | CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCC(CNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)CN(C)C)c1)c1cc(OC)c(OC)c(OC)c1 |
| Relative Density. | 1.192 g/cm3 (Predicted) |
| Storage | Store at low temperature,Keep away from direct sunlight Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (33.72 mM), Sonication is recommended.  Ethanol: 130 mg/mL (87.67 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Saline: < 5 mg/mL (3.37 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (3.37 mM), Solution. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO/Ethanol
Ethanol
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
